- Léčba diabetika inhibitory SGLT2 pro praxi2020 | First Faculty of Medicine
- Inhibitory SGLT2 jsou renoprotektivní i u nediabetických onemocnění ledvin2021 | First Faculty of Medicine
- Current use of SGLT2 inhibitors in type 2 diabetes mellitus2016 | First Faculty of Medicine
- Renoprotective effects of SGLT2 inhibitors - gliflozins2021 | First Faculty of Medicine
- Current position of SGLT2 inhibitors (gliflozins) in the treatment of diabetes mellitus2018 | Second Faculty of Medicine
- Empagliflozin and current position SGLT2 inhibitors in the treatment of type 2 diabetes2015 | First Faculty of Medicine
- New treatment options for chronic kidney disease - focused on SGLT2 inhibitors2021 | First Faculty of Medicine
- Jakým mechanismem působí glifloziny (inhibitory SGLT2) renoprotektivně?2021 | First Faculty of Medicine
- The renoprotective effects of canagliflozin demonstrated in the CREDENCE study cannot yet be considered as an effect of the whole class of SGLT2 inhibitors2020 | Second Faculty of Medicine
- Kardiovaskulární a renální účinky efpeglenatidu, agonisty receptoru pro GLP 1, jsou aditivní k účinkům inhibitorů SGLT22021 | First Faculty of Medicine
- Glucuretics (SGLT2 inhibitors, gliflosine) in the treatment of diabetes2011 | Third Faculty of Medicine
- New mechanism of treatment DM: glifloziny, SGLT2 inhibitors2014 | Second Faculty of Medicine
- Empagliflozin - new SGLT2 inhibitor for diabetes mellitus treatment2014 | Third Faculty of Medicine, First Faculty of Medicine
- SGLT2 inhibitors in the treatment of type 1 diabetic patients2019 | First Faculty of Medicine
- SGLT2 inhibitors and atherosclerosis in a background of effect of gliflozins and heart failure2021 | First Faculty of Medicine
- Dapagliflozin: aspects of clinical use2014 | Second Faculty of Medicine
- Inhibitory SGLT2 v primární prevenci diabetu a v léčbě srdečního selhání - zaměřeno na dapagliflozin2020 | First Faculty of Medicine
- News in the treatment of heart failure - gliflozins in patients with a mildly reduced and preserved ejection fraction2023 | First Faculty of Medicine
- Mechanismy kardioprotektivních a nefroprotektivních účinků inhibitorů SGLT2 nejen u pacientů s diabetem 2. typu2020 | First Faculty of Medicine
- Co je nového v diagnostice a léčbě srdečního selhání na začátku roku 2021?2021 | First Faculty of Medicine
- Komentář k článku Inhibitory SGLT2 a GLP-1 receptoroví agonisté u diabetu 2. typu: rychlé doporučení BMJ2022 | First Faculty of Medicine
- Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology - summary of the document prepared by CKS2020 | First Faculty of Medicine
- 2021 ACC update of the heart failure guidelines2021 | First Faculty of Medicine
- Empagliflozin: Basic clinical characteristics2015 | First Faculty of Medicine
- Dapagliflozin - a new option in treating type 2 diabetes mellitus2015 | Second Faculty of Medicine
- Additional options in diabetes treatment - gliflozins2014 | Faculty of Medicine in Hradec Králové
- Komentář ke studii (Účinnost a bezpečnost dapagliflozinu u pacientů s nedostatečnou kontrolou diabetes mellitus 1. typu - studie DEPICT-1)2018 | First Faculty of Medicine
- Modern therapy of type 1 diabetes in children +12021 | Second Faculty of Medicine
- Farmakoterapie arteriální hypertenze u obézních pacientů s diabetes mellitus 2. typu2023 | First Faculty of Medicine
